125 related articles for article (PubMed ID: 12769667)
1. Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans.
White IN
Curr Drug Metab; 2003 Jun; 4(3):223-39. PubMed ID: 12769667
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins.
Dehal SS; Kupfer D
Drug Metab Dispos; 1999 Jun; 27(6):681-8. PubMed ID: 10348797
[TBL] [Abstract][Full Text] [Related]
3. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
4. Alpha-hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro.
Boocock DJ; Maggs JL; White IN; Park BK
Carcinogenesis; 1999 Jan; 20(1):153-60. PubMed ID: 9934863
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of antiestrogens.
Hirsimäki P; Aaltonen A; Mäntylä E
Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
[TBL] [Abstract][Full Text] [Related]
6. The tamoxifen dilemma.
White IN
Carcinogenesis; 1999 Jul; 20(7):1153-60. PubMed ID: 10383884
[TBL] [Abstract][Full Text] [Related]
7. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.
Styles JA; Davies A; Lim CK; De Matteis F; Stanley LA; White IN; Yuan ZX; Smith LL
Carcinogenesis; 1994 Jan; 15(1):5-9. PubMed ID: 8293548
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation of tamoxifen in a human endometrial explant culture model.
Sharma M; Shubert DE; Sharma M; Lewis J; McGarrigle BP; Bofinger DP; Olson JR
Chem Biol Interact; 2003 Dec; 146(3):237-49. PubMed ID: 14642736
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene.
Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW
Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810
[TBL] [Abstract][Full Text] [Related]
10. Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts.
Boocock DJ; Maggs JL; Brown K; White IN; Park BK
Carcinogenesis; 2000 Oct; 21(10):1851-8. PubMed ID: 11023543
[TBL] [Abstract][Full Text] [Related]
11. Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells).
Styles JA; Davies A; Davies R; White IN; Smith LL
Carcinogenesis; 1997 Feb; 18(2):303-13. PubMed ID: 9054622
[TBL] [Abstract][Full Text] [Related]
12. DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives.
Gamboa da Costa G; McDaniel-Hamilton LP; Heflich RH; Marques MM; Beland FA
Carcinogenesis; 2001 Aug; 22(8):1307-15. PubMed ID: 11470763
[TBL] [Abstract][Full Text] [Related]
13. Anti-oestrogenic drugs and endometrial cancers.
White IN
Toxicol Lett; 2001 Mar; 120(1-3):21-9. PubMed ID: 11323158
[TBL] [Abstract][Full Text] [Related]
14. Genotoxic mechanism of tamoxifen in developing endometrial cancer.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Rev; 2004 May; 36(2):199-218. PubMed ID: 15237851
[TBL] [Abstract][Full Text] [Related]
15. DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen derivatives in vitro.
Okubo T; Nagai F; Ushiyama K; Yokoyama Y; Ozawa S; Kano K; Tomita S; Kubo H; Kano I
Cancer Lett; 1998 Jan; 122(1-2):9-15. PubMed ID: 9464485
[TBL] [Abstract][Full Text] [Related]
16. Determination of DNA damage in F344 rats induced by geometric isomers of tamoxifen and analogues.
Brown K; Brown JE; Martin EA; Smith LL; White IN
Chem Res Toxicol; 1998 May; 11(5):527-34. PubMed ID: 9585484
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen therapy: uncertainties and risk assessment.
Smith LL; White IN
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786
[TBL] [Abstract][Full Text] [Related]
18. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Gauthier S; Luu-The V; Mérand Y; Giguere V; Candas B; Luo S; Martel C; Singh SM; Fournier M; Coquet A; Richard V; Charbonneau R; Charpenet G; Tremblay A; Tremblay G; Cusan L; Veilleux R
J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
[TBL] [Abstract][Full Text] [Related]
19. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.
Boocock DJ; Brown K; Gibbs AH; Sanchez E; Turteltaub KW; White IN
Carcinogenesis; 2002 Nov; 23(11):1897-901. PubMed ID: 12419838
[TBL] [Abstract][Full Text] [Related]
20. alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes.
Phillips DH; Carmichael PL; Hewer A; Cole KJ; Poon GK
Cancer Res; 1994 Nov; 54(21):5518-22. PubMed ID: 7923188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
